Discovery and evaluation of biphenyl derivatives of 2‐iminobenzimidazoles as prototype dual PTP1B inhibitors and AMPK activators with in vivo antidiabetic activity
Chemical Biology & Drug Design · 2023
DOI: 10.1111/cbdd.14198 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2023. Verfasst von Denis A Babkov und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Bioinformatics, Volgograd State Medical University, Volgograd, Russia. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Ministry of Education and Science of the Russian Federation, Russian Science Foundation.
Abstract (Originalsprache)
This work describes the synthesis of series hydrobromides of N ‐(4‐biphenyl)methyl– N ′‐dialkylaminoethyl‐2‐iminobenzimidazoles, which, due to the presence of two privileged structural fragments (benzimidazole and biphenyl moieties), can be considered as bi‐privileged structures. Compound 7a proved to activate AMP‐activated kinase (AMPK) and simultaneously inhibit protein tyrosine phosphatase 1B (PTP1B) with similar potency. This renders it an interesting prototype of potential antidiabetic agents with a dual‐target mechanism of action. Using prove of concept in vivo study, we show that dual‐targeting compound 7a has a disease‐modifying effect in a rat model of type 2 diabetes mellitus via improving insulin sensitivity and lipid metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology & Bioinformatics, Volgograd State Medical University, Volgograd, Russia.
- Scientific Center for Innovative Drugs, Volgograd State Medical University, Volgograd, Russia.
- Institute of Physical and Organic Chemistry, Southern Federal University, Rostov-on-Don, Russia.
- Department of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar, India.
ORCID-Profile: Abbas Haider S Abbas
Förderung
- Ministry of Education and Science of the Russian Federation
- Russian Science Foundation
Zitieren
APA
Babkov, D. A., Zhukovskaya, O. N., Brigadirova, A. A., Prilepskaya, D. R., Kolodina, A. A., Abbas, A. H. S., Morkovnik, A. S., Sobhia, M. E., Ghosh, K., & Spasov, A. A. (2023). Discovery and evaluation of biphenyl derivatives of 2‐iminobenzimidazoles as prototype dual PTP1B inhibitors and AMPK activators with in vivo antidiabetic activity. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14198
Vancouver
Babkov DA, Zhukovskaya ON, Brigadirova AA, Prilepskaya DR, Kolodina AA, Abbas AHS, et al. Discovery and evaluation of biphenyl derivatives of 2‐iminobenzimidazoles as prototype dual PTP1B inhibitors and AMPK activators with in vivo antidiabetic activity. Chemical Biology & Drug Design. 2023. doi:10.1111/cbdd.14198
BibTeX
@article{Babkov2023,
author = {Babkov, Denis A and Zhukovskaya, Olga N and Brigadirova, Anastasia A and Prilepskaya, Diana R and Kolodina, Alexandra A and Abbas, Abbas Haider S and Morkovnik, Anatolii S and Sobhia, M Elizabeth and Ghosh, Ketan and Spasov, Alexander A},
title = {Discovery and evaluation of biphenyl derivatives of 2‐iminobenzimidazoles as prototype dual PTP1B inhibitors and AMPK activators with in vivo antidiabetic activity},
journal = {Chemical Biology & Drug Design},
year = {2023},
doi = {10.1111/cbdd.14198}
}
EUVIMED